Mylan N.V. (MYL) : Wednesdays money flow indicated an uptick to downtick ratio was at 1.09. The total value of inflow transactions on upticks was $35.65 million, whereas, the total value of outflow trades on downticks was $32.74 million. The total money flow was $2.91 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $5.55 million. The total value of the trades done on upticks was $9.98 million. Downticks saw transactions worth $4.44 million. The total uptick to downtick ratio stood at 2.25, mildly in favor of the bulls. Mylan N.V. (MYL) was trading with a -2.64% change over previous days close. It fell $1.09 during the day and reached $40.22. The stock was -4.37% compared to the previous weeks close.
Mylan N.V. has lost 4.03% in the last five trading days and dropped 6.94% in the last 4 weeks. Mylan N.V. has dropped 6.94% during the last 3-month period . Year-to-Date the stock performance stands at -25.61%.
Mylan N.V. (MYL) : Zacks Investment Research ranks Mylan N.V. (MYL) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 2.33, which indicates as a Buy.
Mylan N.V. (NASDAQ:MYL): stock was range-bound between the intraday low of $40.04 and the intraday high of $41.43 after having opened at $41.2 on Wednesdays session. The stock finally closed in the red at $41.2, a loss of -2.64%. The stock remained in the red for the whole trading day. The total traded volume was 5,648,023 shares. The stock failed to cross $41.43 in Wednesdays trading. The stocks closing price on Thursday was $41.31.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.